PUBLISHER: Acute Market Reports | PRODUCT CODE: 1166112
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1166112
Angiotensin Converting Enzyme (ACE) Inhibitors Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
This report titled angiotensin converting enzyme (ACE) inhibitors market studies various drug type, application type and geographical scenario. According to Cleveland Clinic, an ACE inhibitor is a type of vasodilator that dilates the blood vessels to improve the amount of blood the heart pumps in patients suffering from high blood pressure. An ACE inhibitor also increases blood flow, which will help decrease the amount of work the heart has to do and may also decrease your blood pressure. The renin-angiotensin-aldos-terone system (RAAS) plays a key physiologic role in the regulation of blood pressure in the human body. In RAAS, ACE plays an important role in the production of angiotensin II where it facilitates the conversion of the biologically inactive angiotensin I to angiotensin II. Angiotensin II increases blood pressure by its action as a potent vasoconstrictor and stimulates the production of aldosterone, which promotes sodium and water retention in the body. Therefore, a substance that inhibits ACE will decrease the production of angiotensin II and reduce blood pressure. According to World Health Organization (WHO), high blood pressure is one of the most important causes of premature death worldwide killing nearly 9.4 million people every year globally, and the problem is growing. The WHO data further suggested that the prevalence of raised blood pressure was highest in the African Region (46%) and lowest in the Region of the Americas (35%). In the South-East Asia Region, 36% of adults have hypertension. Thus, rising prevalence of hypertension and diabetes, and high public awareness related with early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitors market.
The major key players profiled in the ACE inhibitors market are on the basis of various characteristics such as business description, financial health and budget allocation, product portfolio, and news coverage. The key players profiled in this report are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Jhonson and Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Angiotensin Converting Enzyme (ACE) Inhibitors market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report
Micro and macro environment factors that are currently influencing the Angiotensin Converting Enzyme (ACE) Inhibitors market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug Type
Benazepri
Captopril
Enalapril
Fosinopril
Lisinopril
Moexipril
Perindopril
Quinapril
Ramipril
Trandolapril
Combination ACE Inhibitors
Application
Hypertension
Coronary Artery Diseases
Heart Failure
Myocardial Infarction
Diabetes
Chronic Kidney Disorders
Others (Scleroderma, Migraine and others)
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of Covid-19 Segment (2020-2021; US$ Million )
Pre Covid-19 situation
Post Covid-19 situation
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Angiotensin Converting Enzyme (ACE) Inhibitors market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Angiotensin Converting Enzyme (ACE) Inhibitors market?
Which is the largest regional market for Angiotensin Converting Enzyme (ACE) Inhibitors market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Angiotensin Converting Enzyme (ACE) Inhibitors market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Angiotensin Converting Enzyme (ACE) Inhibitors market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Angiotensin Converting Enzyme (ACE) Inhibitors Market
- 2.2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Type, 2021 (US$ Million)
- 2.3. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application, 2021 (US$ Million)
- 2.4. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Geography, 2021 (US$ Million)
- 2.5. Impact of Covid 19
- 2.6. Attractive Investment Proposition by Geography, 2021
- 2.7. Competitive Analysis
- 2.7.1. Market Positioning of Key Angiotensin Converting Enzyme (ACE) Inhibitors Market Vendors
- 2.7.2. Strategies Adopted by Angiotensin Converting Enzyme (ACE) Inhibitors Market Vendors
- 2.7.3. Key Industry Strategies
3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: Business Outlook & Market Dynamics
- 3.1. Introduction
- 3.2. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Value, 2020 - 2030, (US$ Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers
- 3.3.2. Market Restraints
- 3.3.3. Key Challenges
- 3.3.4. Key Opportunities
- 3.4. Impact Analysis of Drivers and Restraints
- 3.5. See-Saw Analysis
- 3.6. Porter's Five Force Model
- 3.6.1. Supplier Power
- 3.6.2. Buyer Power
- 3.6.3. Threat Of Substitutes
- 3.6.4. Threat Of New Entrants
- 3.6.5. Competitive Rivalry
- 3.7. PESTEL Analysis
- 3.7.1. Political Landscape
- 3.7.2. Economic Landscape
- 3.7.3. Technology Landscape
- 3.7.4. Legal Landscape
- 3.7.5. Social Landscape
4. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
- 4.1. Market Overview
- 4.2. Growth & Revenue Analysis: 2021 Versus 2030
- 4.3. Market Segmentation
- 4.3.1. Benazepri
- 4.3.2. Captopril
- 4.3.3. Enalapril
- 4.3.4. Fosinopril
- 4.3.5. Lisinopril
- 4.3.6. Moexipril
- 4.3.7. Perindopril
- 4.3.8. Quinapril
- 4.3.9. Ramipril
- 4.3.10. Trandolapril
- 4.3.11. Combination ACE Inhibitors
5. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Hypertension
- 5.3.2. Coronary Artery Diseases
- 5.3.3. Heart Failure
- 5.3.4. Myocardial Infarction
- 5.3.5. Diabetes
- 5.3.6. Chronic Kidney Disorders
- 5.3.7. Others (Scleroderma, Migraine and others)
6. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
- 6.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
- 6.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
- 6.4.1.North America
- 6.4.1.1. U.S.
- 6.4.1.2. Canada
- 6.4.1.3. Rest of North America
- 6.4.1.North America
7. UK and European Union Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
- 7.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
- 7.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
- 7.4.1.UK and European Union
- 7.4.1.1. UK
- 7.4.1.2. Germany
- 7.4.1.3. Spain
- 7.4.1.4. Italy
- 7.4.1.5. France
- 7.4.1.6. Rest of Europe
- 7.4.1.UK and European Union
8. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
- 8.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
- 8.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
- 8.4.1.Asia Pacific
- 8.4.1.1. China
- 8.4.1.2. Japan
- 8.4.1.3. India
- 8.4.1.4. Australia
- 8.4.1.5. South Korea
- 8.4.1.6. Rest of Asia Pacific
- 8.4.1.Asia Pacific
9. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
- 9.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
- 9.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
- 9.4.1.Latin America
- 9.4.1.1. Brazil
- 9.4.1.2. Mexico
- 9.4.1.3. Rest of Latin America
- 9.4.1.Latin America
10. Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Drug Type, 2020-2030, USD (Million)
- 10.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Application, 2020-2030, USD (Million)
- 10.4.Angiotensin Converting Enzyme (ACE) Inhibitors Market: By Region, 2020-2030, USD (Million)
- 10.4.1.Middle East and Africa
- 10.4.1.1. GCC
- 10.4.1.2. Africa
- 10.4.1.3. Rest of Middle East and Africa
- 10.4.1.Middle East and Africa
11. Company Profile
- 11.1. Abbott Laboratories
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Initiatives
- 11.2. Pfizer, Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Initiatives
- 11.3. Novartis AG
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Portfolio
- 11.3.4. Strategic Initiatives
- 11.4. Merck & Co.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Initiatives
- 11.5. Astra Zeneca plc
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Initiatives
- 11.6. Jhonson and Johnson Limited
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Portfolio
- 11.6.4. Strategic Initiatives
- 11.7. Eli Lilly and Company
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Portfolio
- 11.7.4. Strategic Initiatives
- 11.8. Sanofi SA
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Portfolio
- 11.8.4. Strategic Initiatives
- 11.9. Bristol-Myers Squibb Company
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Portfolio
- 11.9.4. Strategic Initiatives
- 11.10. Bayer AG
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Portfolio
- 11.10.4. Strategic Initiatives
- 11.11. GlaxoSmithKline plc
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Portfolio
- 11.11.4. Strategic Initiatives
- 11.12. Teva Pharmaceutical Industries Ltd.
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Portfolio
- 11.12.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
- TABLE 2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
- TABLE 3 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
- TABLE 4 North America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
- TABLE 5 UK and European Union Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
- TABLE 6 UK and European Union Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
- TABLE 7 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
- TABLE 8 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
- TABLE 9 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
- TABLE 10 Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
- TABLE 11 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug Type, 2020-2030, USD (Million)
- TABLE 12 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market By Application, 2020-2030, USD (Million)
List of Figures
- FIG. 1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Quality Assurance
- FIG. 5 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Type, 2021
- FIG. 6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application, 2021
- FIG. 7 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Geography, 2021
- FIG. 8 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drug Type, 2021 Vs 2030, %
- FIG. 9 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Application, 2021 Vs 2030, %
- FIG. 10 U.S. Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 11 Canada Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 12 Rest of North America Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 13 UK Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 14 Germany Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 15 Spain Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 16 Italy Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 17 France Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 18 Rest of Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 19 China Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 20 Japan Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 21 India Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 22 Australia Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 23 South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 24 Rest of Asia Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 25 Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 26 Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 27 Rest of Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 28 GCC Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 29 Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
- FIG. 30 Rest of Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market (US$ Million), 2020 - 2030
